EXHIBIT 99.1
                                  ------------

      THE  SECURITIES  REPRESENTED  HEREBY  HAVE BEEN  ISSUED  WITHOUT
      REGISTRATION  UNDER THE SECURITIES  ACT OF 1933, AS AMENDED,  OR
      UNDER  ANY  STATE   SECURITIES   LAWS,  AND  MAY  NOT  BE  SOLD,
      TRANSFERRED   OR  PLEDGED  IN  THE   ABSENCE  OF  AN   EFFECTIVE
      REGISTRATION   STATEMENT  UNDER  APPLICABLE  FEDERAL  AND  STATE
      SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY
      TO THE COMPANY  THAT THE  TRANSFER  IS EXEMPT FROM  REGISTRATION
      UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS.

                         THE IMMUNE RESPONSE CORPORATION
                     8% CONVERTIBLE SECURED PROMISSORY NOTE
                     --------------------------------------

$4,000,000                                                    New York, New York
                                                                     May 3, 2002

            FOR the receipt of  $1,980,712.33  in cash and the  cancellation  of
$2,000,000 of principal indebtedness plus $19,287.67 interest represented by the
8% Secured Promissory Note dated March 20, 2002 from the Issuer to the Purchaser
(as defined below), the undersigned, The Immune Response Corporation, a Delaware
corporation (the "Issuer"),  hereby unconditionally  promises to pay on the Note
Maturity  Date (as  defined  in that  certain  Note  Purchase  Agreement,  dated
November 9, 2001, by and between the Purchaser,  Kevin Kimberlin Partners, L.P.,
a Delaware limited  partnership,  and the Issuer,  and as amended as of February
14, 2002 and further amended as of May 3, 2002 (the "Note Purchase  Agreement"))
to the order of Oshkim Limited Partnership,  a Delaware limited partnership (the
"Purchaser"), at the office of the Purchaser located at 535 Madison Avenue, 18th
Floor,  New York,  New York  10022,  or such  other  address  designated  by the
Purchaser,  in lawful money of the United  States of America and in  immediately
available funds,  the principal amount of (a) Four Million Dollars  ($4,000,000)
or (b) if less as a result of any voluntary  conversion(s)  of this Note in part
in  accordance  with Section 3.4 of the Note Purchase  Agreement,  the aggregate
unpaid  principal  amount  of this  Note.  Subject  to  Section  3.4 of the Note
Purchase  Agreement,  the Issuer  further  agrees to pay  interest on the unpaid
principal amount outstanding  hereunder from time to time, from the date hereof,
in like money,  at the rate of eight (8%) percent per annum, as and at the dates
specified in Section 3.3 of the Note Purchase Agreement.

            This Note is one of the  promissory  notes  referred  to in the Note
Purchase  Agreement,  and is entitled  to the  benefits  thereof,  is secured as
provided therein (and as provided in that certain Intellectual Property Security
Agreement,  dated November 9, 2001,  executed by the Issuer and as amended as of
February 14, 2002) and is subject to  conversion  as set forth  therein.  In the
event of any conflict  between the Note Purchase  Agreement  and this Note,  the
terms and provisions of the Note Purchase Agreement shall govern.

            Upon the  occurrence  of any one or more of the  Events  of  Default
specified in the Note Purchase  Agreement,  all amounts then remaining unpaid on
this Note shall become,  or may be declared to be,  immediately due and payable,
all as provided in the Note Purchase Agreement.



            Subject to the  provisions of the legend above,  this Note is freely
transferable,  in whole or in part, by the Purchaser,  and such transferee shall
have the same rights  hereunder as the  Purchaser.  The Issuer may not assign or
delegate  any of its  obligations  under  this Note  without  the prior  written
consent of the Purchaser (or its successor, transferee or assignee).

            All parties  now and  hereafter  liable  with  respect to this Note,
whether maker, principal, surety, guarantor, endorser or otherwise, hereby waive
presentment, demand, protest and all other notices of any kind.
            Subject to Section 3.3 of the Note Purchase Agreement, the Issuer
agrees to pay all of the Purchaser's expenses, including reasonable attorneys'
costs and fees, incurred in collecting sums due under this Note.

            This Note shall be subject to prepayment only in accordance with the
terms of the Note Purchase Agreement.

            This Note shall be governed by, and  construed  and  interpreted  in
accordance with, the laws of the State of New York.

                                    THE IMMUNE RESPONSE CORPORATION



                                    By:__________________________
                                       Name:______________________
                                       Title:_____________________



                                      -2-